Cover Image
市場調查報告書

中國的Rituximab市場分析

Investigation Report on China Rituximab Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 296864
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Rituximab市場分析 Investigation Report on China Rituximab Market, 2010-2019
出版日期: 2015年05月28日 內容資訊: 英文 30 Pages
簡介

Rituximab(Roche公司「MabThera」、Genentech公司「Rituxan」)是1997年已核准的腫瘤治療藥──對CD20抗原的嵌合單株抗體。在治療B細胞淋巴瘤上非常有效,展現出良好的抗性。全球Rituximab市場銷售額在2011年為61億4,000萬美元,2012年為71億4,300萬美元,之後順利成長,到2014年超過80億美金的規模。

本報告提供中國的Rituximab市場相關調查分析、提供主要廠商的市場佔有率、醫院市場上的銷售價格、醫院市場上的市場佔有率(各劑型)、自體免疫疾病的發病率、學名藥的製造計劃、市場預測等資訊,為您概述為以下內容。

第1章 Rituximab的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的Rituximab的市場概要

  • 專利狀況
  • 主要製造商
  • 市場規模

第3章 中國的Rituximab的銷售額分析

  • 整體銷售額
  • 銷售額:各地區

第4章 中國的Rituximab的主要廠商的市場佔有率分析

  • 市場佔有率:各銷售額
  • 市場佔有率:各銷售量

第5章 中國的Rituximab(各劑型)的市場規模分析

  • 市場佔有率:各銷售額、劑型
  • 市場佔有率:各銷售量、劑型

第6章 中國的醫院市場上Rituximab的標準價格

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

第7章 中國的Rituximab的主要製造商

  • Hoffmann-La Roche, Inc.
  • Roche Diagnostics
  • Shanghai Roche Pharmaceutical Co., Ltd.

第8章 中國的Rituximab市場預測

  • 非何杰金氏淋巴瘤、自體免疫疾病的發病率的預測
  • Rituximab市場規模的預測
  • Rituximab競爭格局的預測

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1505181

Rituximab (trade name is Rituxan by Roche) was a human-mouse chimeric anti-CD20 monoclonal antibody approved by FDA to treat tumor in 1997. The treatment range of Rituximab extends from B-cell malignant tumors to rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura and such autoimmune diseases. In 2014, the sales revenue of Rituxan exceeded USD 8 billion.

In China, the incidence of non-Hodgkin lymphoma fast rises from 20/1 million at the end of 20 century to 70/1 million nowadays. Autoimmune diseases can harm central nervouos system and organs such as lung, liver and kidney, leading to organ dysfunction and even organ failure. All of them can be life threatening. Statistics shows that there are approximately 30 to 40 million people suffering from autoimmune diseases in China. Such incidence is high enough to attract people's attention.

By the second quarter of 2015, there is no Rituximab produced by Chinese domestic enterprise on the market. The market is wholly occupied by products of Roche. Early 2014, monoclonal antibody drug "recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection" produced by Hisun was approved clinical. It is generic drug of Rituximab of Roche. Five manufacturers in China have reported clinical use of rituximab generic drug. It is estimated that more generic drugs will go on the market in the next few years. According to CRI's investigation on certain sample hospitals in China, the CAGR of sales value of rituximab surpassed 30% from 2005 to 2014. Rituximab is expected to have huge room to grow in future Chinese market.

Through this report, the readers can acquire the following information:

  • Market Share of Major Rituximab Manufacturers in China Sample Hospitals
  • Sales Price of Rituximab in China Hospital Market
  • Market Share of Rituximab by Dosage Form in China Hospital Market
  • Incidence of Autoimmune Diseases in China
  • Manufacturing Schedule of Rituximab Generic Drug
  • Prospect of China Rituximab Market

The Following Enterprises and People Are Recommended to Purchase This Report:

  • Manufacturers of Crude and Finished Monoclonal Antibody Remedy
  • Medical Institutions
  • Investors/Research Institutes Focusing on Monoclonal Antibody Market
  • CRI also provides custom research focusing on China monoclonal antibody market.

Table of Contents

1. Relevant Concepts of Rituximab

  • 1.1. Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Rituximab in China, 2010-2014

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Rituximab in China, 2010-2014

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Rituximab Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Rituximab by Dosage Form in China, 2010-2014

  • 5.1. Market Share by Sales Value and Dosage Form
  • 5.2. Market Share by Sales Volume and Dosage Form

6. Reference Price of Rituximab in China Hospital Market, 2014

  • 6.1. Hoffmann-La Roche, Inc.
  • 6.2. Roche Diagnostics
  • 6.3. Shanghai Roche Pharmaceutical Co., Ltd.

7. Analysis on Major Rituximab Manufacturers in China

  • 7.1. Hoffmann-La Roche, Inc.
  • 7.2. Roche Diagnostics
  • 7.3. Shanghai Roche Pharmaceutical Co., Ltd.

8. Prospect of China Rituximab Market, 2015-2019

  • 8.1. Forecast on Incidence of non-Hodgkin lymphoma and Autoimmune Disease
  • 8.2. Forecast on Rituximab Market Size
  • 8.3. Forecast on Rituximab Competition Pattern

Selected Charts

  • Chart Rituximab Products Approved to Market in China, 2014
  • Chart Sales Value of Rituximab in Global Market, 2010-2014
  • Chart Sales Value of Rituximab in Hospital Market in China, 2010-2014
  • Chart Sales Value of Rituximab by Region in China, 2010-2014
  • Chart Market Share of Rituximab Enterprises by Sales Value in China, 2010-2014
  • Chart Price of Rituximab Produced by Hoffmann-La, Inc. in China Hospital Market
  • Chart Price of Rituximab Produced by Shanghai Roche in China Hospital Market
  • Chart Forecast on Market Size of Hospital-use Rituximab in China, 2015-2019
  • Chart Status Quo of Rituximab Generic Drug in China Market
Back to Top